Innate Pharma S.A. (IPHA)
Stock Price:
$3.90 USD
-0.01 (-0.26%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
307.95M |
| Revenue (ttm) |
96.42M |
| Net Income (ttm) |
-20.76M |
| Shares Out |
78.96M |
| EPS (ttm) |
-0.35 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$3.90 |
| Previous Close |
$3.91 |
| Change ($) |
-0.01 |
| Change (%) |
-0.26% |
| Day's Open |
3.90 |
| Day's Range |
3.88 - 3.96 |
| Day's Volume |
3,872 |
| 52-Week Range |
3.30 - 8.24 |
More Stats
| Market Cap |
307.95M |
| Enterprise Value |
83.07M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
78.96M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.35 |
| FCF / Share |
0.51 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
12.28% |
| Payout Ratio |
n/a |
| Shares Short |
22,653 |
| Short Ratio |
1.67 |
| Short % of Float |
n/a |
| Beta |
-0.11 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
8.14 |
| PS Ratio |
3.19 |
| PB Ratio |
1.35 |
| Revenue |
96.42M |
| Operating Income |
-30.40M |
| Net Income |
-20.76M |
| Free Cash Flow |
37.81M |
| Net Cash |
224.88M |
| Net Cash / Share |
2.84 |
| Gross Margin |
100.00% |
| Operating Margin |
-31.52% |
| Profit Margin |
-24.20% |
| FCF Margin |
39.22% |
| ROA |
-8.18% |
| ROE |
-22.79% |
| ROIC |
-153.50% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
4 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$10.35*
(165.38% upside)
Low
4.68
Current: $3.90
High
17.50
Target: 10.35
*Average 12-month USD price target from 6 stock analysts.
Financial Performance
Financial numbers in millions EUR.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 85.81 | 93.95 | 44.03 |
| Revenue Growth | -8.66% | 113.37% | - |
| Gross Profit | 85.81 | 93.95 | 44.03 |
| Operating Income | -27.05 | 5.15 | -39.98 |
| Net Income | -20.76 | 3.05 | -48.39 |
| Shares Outstanding | 74.71 | 58.78 | 54.35 |
| Earnings Per Share | -0.31 | 0.05 | -0.89 |
| Operating Cash Flow | 34.92 | -32.53 | -48.06 |
| Capital Expenditures | -1.27 | -0.85 | -2.91 |
| Free Cash Flow | 33.65 | -33.38 | -50.97 |
| Cash & Equivalents | 219 | 168 | 116 |
| Total Debt | 18.72 | 4.52 | 5.86 |
| Net Cash / Debt | 200 | 163 | 110 |
| Assets | 401 | 451 | 255 |
| Liabilities | 184 | 284 | 169 |
| Book Value | 217 | 167 | 85.96 |
Numbers in millions EUR, except per-share numbers.
Company Details
| Full Name |
Innate Pharma S.A. |
| Country |
France |
| Employees |
247 |
| CEO |
Mondher Mahjoubi |
Stock Information
| Ticker Symbol |
IPHA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IPHA |
| IPO Date |
October 17, 2019 |
Description
Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.